History of 7,093 Patients with Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia Treated with Alfuzosin in General Practice up to 3 Years

Lukacs, B.; Grange, J.C.; Comet, D.; McCarthy, Caitlin

doi:10.1159/000020116

Cited by 33 publications

(18 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The design and chemistry of 5-alpha-reductase inhibitors has been thoroughly studied and reviewed 31. The most extensively studied are the 17b-substituted-4-azasteroids of which two (finasteride and dutasteride) are now approved for human use.…”

Section: -Alpha-reductase Inhibitorsmentioning

confidence: 99%

Therapeutic options in the treatment of benign prostatic hyperplasia

Sandhu¹

2009

PPA

View full text Add to dashboard Cite

Current theraputic options for the treatment of symptomatic benign prostatic hyperplasia (BPH) are reviewed. Therapeutic options for mild lower urinary tract symptoms (LUTS), as defined by the American Urological Association, are generally treated medically. Moderate to severe LUTS can be treated medically or with surgical therapy. Current medical and surgical treatments for LUTS secondary to BPH are reviewed and evolving treatments are explored.

show abstract

Section: -Alpha-reductase Inhibitorsmentioning

confidence: 99%

Therapeutic options in the treatment of benign prostatic hyperplasia

Sandhu¹

2009

PPA

View full text Add to dashboard Cite

show abstract

“…The elderly especially have a less dynamic adaptation to orthostatic stress, as they tend to rely more on the homeostatic contribution of ancillary vasoconstriction, and have a reduced vascular compliance and a disturbed responsiveness of the heart to vagal stimulation [43]. Open‐label, observational studies with alfuzosin 2.5 mg tid showed that this formulation of alfuzosin induced more cardiovascular AEs in the elderly (≥75 years) than in younger patients [44–46]. Alfuzosin 2.5 mg tid also showed a greater potential for inducing cardiovascular AEs in patients with cardiovascular comorbidity and/or comedication [44–46].…”

Section: Tolerability Of α1‐ar Antagonistsmentioning

confidence: 99%

Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on α₁‐adrenoceptor antagonists

2005

View full text Add to dashboard Cite

SUMMARY An update of a systematic review of α1‐adrenoceptor (AR) antagonists in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) showed that these agents have comparable efficacy. The total symptom score is improved by 30–45% and maximum urinary flow rate by 15–30% vs baseline. α1‐AR antagonists that can be started at their therapeutic dose have a more rapid onset of action than α1‐AR antagonists that have to be titrated. α1‐AR antagonists can be differentiated according to their tolerability. Alfuzosin (especially the 10 mg once daily dose) and tamsulosin (especially the 0.4 mg once daily dose) are better tolerated than doxazosin and terazosin. However, alfuzosin might induce more cardiovascular adverse events (AEs) in the elderly and/or patients with cardiovascular comorbidity and/or comedication. Tamsulosin tends to interfere less with blood pressure regulation and induce less vasodilatory AEs than alfuzosin, especially in the elderly, and is well tolerated in patients with cardiovascular comorbidity and/or comedication. Cardiovascular AEs might lead to potentially serious complications such as falls, fractures and institutionalization. Abnormal ejaculation has mainly been reported in placebo‐controlled trials with tamsulosin but in direct comparative trials its rate with tamsulosin 0.4 mg was similar to, or only slightly higher than, the rate with alfuzosin. In addition, abnormal ejaculation is not reported as bothersome by the patient or associated with serious complications. It can be concluded that an α1‐AR antagonist with a low potential to interfere with blood pressure regulation and to induce cardiovascular AEs, also in patients with cardiovascular comorbidity and/or comedication, can be considered a first‐choice treatment option in LUTS/BPH.

show abstract

“…26 Longterm dura bility of the clinical benefits over 3 years were subsequently shown. 27 With the publication of these-and similar-trials, αblockers are now in routine use for the management of men with BPH. Also in 1992, the unequivocal clinical benefit of finasteride was shown, introdu cing the concept of 'prostate shrinkage' to clinical practice.…”

Section: Medical Managementmentioning

confidence: 99%

Landmarks in BPH—from aetiology to medical and surgical management

Kahokehr

Gilling

2014

Nat Rev Urol

View full text Add to dashboard Cite

Clinicians treat the symptoms associated with BPH on a daily basis. Although BPH is nearly universal with age, not all men develop lower urinary tract symptoms. Over the past 100 years, several notable advances in the field of urology have not only improved our understanding of the aetiology and natural history of this common disease, but have also facilitated the development of therapeutics to effectively manage BPH-related symptoms. The high quality of modern-day diagnosis, as well as medical and surgical treatment for BPH, is a testimony to centuries of observation and decades of scientific research.

show abstract

History of 7,093 Patients with Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia Treated with Alfuzosin in General Practice up to 3 Years

Cited by 33 publications

References 25 publications

Therapeutic options in the treatment of benign prostatic hyperplasia

Therapeutic options in the treatment of benign prostatic hyperplasia

Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on α₁‐adrenoceptor antagonists

Landmarks in BPH—from aetiology to medical and surgical management

Contact Info

Product

Resources

About

History of 7,093 Patients with Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia Treated with Alfuzosin in General Practice up to 3 Years

Cited by 33 publications

References 25 publications

Therapeutic options in the treatment of benign prostatic hyperplasia

Therapeutic options in the treatment of benign prostatic hyperplasia

Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on α1‐adrenoceptor antagonists

Landmarks in BPH—from aetiology to medical and surgical management

Contact Info

Product

Resources

About

Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on α₁‐adrenoceptor antagonists